Breast cancer is sensitive to several cytotoxic drugs. Combination cytotoxic regimens are associated with higher response rates and longer durations of response and, occasionally, survival, than are single-agent regimens. However, combination regimens of conventional agents have not changed the course of the disease. In the past decade, numerous newer cytotoxic agents have been developed. Gemci...